论文部分内容阅读
目的研究两剂量赛尼哌对肾移植中急性排斥的预防作用。方法赛尼哌分别在移植前2h和移植后14d给予,术后应用常规三联免疫抑制治疗。结果术后1年时对照组活检证实急性排斥的发生率为22.5%,赛尼哌组急性排斥发生率为6.82%,明显低于对照组。赛尼哌组中肺部感染5例,其中巨细胞病毒(CMV)感染2例,霉菌性肺炎1例,泌尿系感染6例,与对照组比较无显著性差异。使用赛尼哌前后,淋巴细胞变化无明显差异,无发热、头痛、急性肺水肿等细胞因子释放表现。术后1年时赛尼哌组人/肾存活率分别为95.45%/95.45%,对照组人/肾存活率分别为95%/95%。结论两剂量赛尼哌能减少急性排斥的发生,且疗程短,耐受性良好,无细胞因子释放综合征和增加感染并发症。
Objective To study the preventive effects of two doses of saenipir on acute rejection in renal transplantation. Methods: Zenapax was administered at 2 hours before transplantation and 14 days after transplantation, respectively. Conventional triple immunosuppressive therapy was used. Results The rate of acute rejection in the control group was 22.5% at 1 year after surgery and 6.82% at seiripiperazine group, which was significantly lower than that of the control group. 5 cases of pulmonary infection in the saenipid group, including cytomegalovirus (CMV) infection in 2 cases, 1 case of fungal pneumonia, urinary tract infection in 6 cases, compared with the control group no significant difference. Before and after the use of Zenapil, no significant difference in lymphocyte changes, no fever, headache, acute pulmonary edema and other cytokines release performance. The survival rate of human / kidney was 95.45% / 95.45% after 1 year and 95% / 95% respectively in the control group. Conclusions Two doses of saenipid can reduce the incidence of acute rejection, and the course is short, well tolerated, no cytokine release syndrome and increase the complications of infection.